Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-15 · accession 0001209191-22-010384 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-16 | 2022-02-15 | PHIO | Dispersyn Gerrit | Pres, CEO, Dir | A - Grant | $0.00 | +126.0K | 221.3K | +132% | $0 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2022-02-15 | A | A | 126,000 | $0.00 | 221,281 | D | — | — | (F1) Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments. (F2) Includes shares of common stock underlying unvested restricted stock units. |